drugset / Trial / NCT07565220
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic stem cell transplantation (alloSCT).
Timeline
- Start
- 2026-08-01
- Primary completion
- 2029-06-01
- Completion
- 2030-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fludarabine | Small molecule | 30 mg/m2 | — |
| Subject | Fludarabine | Small molecule | 40 mg/m2 | — |
| Background | Busulfan | Small molecule | 3.2 mg/kg | Intravenous |
| Background | Thiotepa | Other / unclassified | 5 mg/kg | — |